Joseph J. Pinzone, MD, MBA, FACP
Dr. Joseph Pinzone is the Medical Director of the Hyperthermia Cancer Institute (HCI). He is also Assistant Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA and a Fellow of the American College of Physicians.
Dr. Pinzone is dedicated to using hyperthermia to optimize the care and clinical outcomes of patients with cancer and aims to lead the field of thermal oncology. He has been involved in tumor biology research and treating patients with cancer for over 20 years. His optimism defines his approach to his patient care and is driven by the accelerating progress we are making in the field of cancer therapy.
“We are continuously improving cancer therapy by discovering new treatments, improving our understanding the mechanisms of established treatments, and learning how to optimally combine treatments to yield the best outcome for patients.”
Dr. Pinzone graduated from New York University School of Medicine and completed internship and residency in Internal Medicine at Columbia-Presbyterian Medical Center. He then completed fellowship in Endocrinology, Diabetes & Metabolism at Massachusetts General Hospital and Harvard University where he achieved a National Research Service Award from the National Institutes of Health (NIH) to investigate the cause of pituitary tumors.
After fellowship, Dr. Pinzone joined the faculty of The George Washington University School of Medicine where he practiced and taught Endocrinology and Internal Medicine. While at GW, he achieved a Master of Business Administration with honors and secured a 5-year research grant from the NIH to study breast cancer.
Dr. Pinzone then joined the faculty of The Ohio State University College of Medicine where his clinical work focused on patients with pituitary conditions. He also headed a molecular biology laboratory where he investigated why breast cancer spreads to bone. While at OSU, Dr. Pinzone taught both Internal Medicine and Endocrinology.
During his time in academic medicine, Dr. Pinzone taught and mentored medical students and physicians, as well as clinical and research scientists. He published multiple peer-reviewed scientific papers and lectured on many clinical and research topics.
Dr. Pinzone was then recruited to Amgen, Inc. where he was Clinical Research Medical Director. He worked in the Hematology/Oncology Therapeutic Area as the North American Medical Leader for the launch of Xgeva® which is used to treat patients with solid tumors to prevent skeletal-related events. He worked in the Bone therapeutic area and focused on Prolia® which is used to treat patients with osteoporosis.
With a diverse background in many aspects of medical care and innovation, Dr. Pinzone now combines his skills in patient care and teaching as well as clinical and basic science research. As Medical Director of HCI, he is motivated to accomplish four goals. First, to offer patients cutting-edge cancer care with hyperthermia. Second, to continue to expand the premiere center for thermal oncology. Third, to increase the awareness of hyperthermia among patients and healthcare providers. Fourth, to innovate and generate novel insights on how best to use hyperthemia in the rapidly advancing field of cancer care.